Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.56 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.55 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.55 |
| ▸ | CASP1 | P29466 | 9/20 | 0.54 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | SYK | P43405 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19285611 | 1.00 | HTT (0.58) | HTTLMNASMN1; SMN2CTRB1SLC1A3 | |
| SCHEMBL6649610 | 0.92 | HTT (0.63) | HTTLMNASMN1; SMN2CTRB1SLC1A3 | |
| SCHEMBL6652290 | 0.92 | HTT (0.63) | HTTLMNASMN1; SMN2CTRB1SLC1A3 | |
| SCHEMBL1024311 | 0.91 | FOLH1 (0.61) | HTTLMNASMN1; SMN2FOLH1 | |
| SCHEMBL7064119 | 0.90 | FOLH1 (0.60) | HTTLMNASMN1; SMN2FOLH1 | |
| SCHEMBL6653860 | 0.90 | FOLH1 (0.60) | HTTLMNASMN1; SMN2FOLH1 | |
| SCHEMBL1022899 | 0.89 | SYK (0.67) | HTTLMNASMN1; SMN2CTRB1SLC1A3 | |
| SCHEMBL20556459 | 0.89 | SYK (0.67) | HTTLMNASMN1; SMN2CTRB1SLC1A3 | |
| SCHEMBL6372825 | 0.89 | SYK (0.60) | HTTLMNASMN1; SMN2CTRB1SLC1A3 | |
| SCHEMBL6372820 | 0.89 | SYK (0.60) | HTTLMNASMN1; SMN2CTRB1SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10556854-B2 | Bacterial efflux pump inhibitors | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190084919-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-03-21 | — | — | US | disclosed |
| WO-2017147333-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-08-31 | — | — | WO | disclosed |
| WO-2017147333-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-08-31 | — | — | WO | disclosed |
| EP-1117652-B1 | TAN-1057 DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2004-05-26 | — | — | EP | disclosed |
| US-6617332-B1 | Cyclic amidinourea derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2003-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10556854-B2 | Bacterial efflux pump inhibitors | ABCB11, ABCB1, SLC47A1 | HTT 4490/4885LMNA 3655/4885SMN1; SMN2 4878/4885 |
| US-20190084919-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | ABCB11, ABCB1, SLC47A1 | HTT 4490/4885LMNA 3655/4885SMN1; SMN2 4878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.